\n Data tracked by StockTitan Argus<\/a> on the day of publication. \n <\/p>\n
\n Near-term milestone
\n $10 million
\n
\n Second milestone payment earned from Novo Nordisk in 2026
\n
\n <\/p>\n
\n Potential near-term milestone
\n $10 million
\n
\n Third milestone payment that may be achieved later in 2026
\n
\n <\/p>\n
\n Total potential payments
\n $1 billion
\n
\n Maximum upfront and milestone payments under LX9851 collaboration
\n
\n <\/p>\n
\n Phase 1 sample size
\n 96 people
\n
\n Participants with overweight or obesity in LX9851 Phase 1 study
\n
\n <\/p>\n
\n Study completion timing
\n Q1 2027
\n
\n Expected completion of LX9851 Phase 1 trial
\n
\n <\/p>\n
\n Dose design
\n Single and multiple ascending doses
\n
\n LX9851 Phase 1 design versus placebo
\n
\n <\/p>\n
\n Potential milestone tranches
\n Three $10 million milestones
\n
\n Series of near-term milestones tied to LX9851 development
\n
\n <\/p>\n
\n Study population
\n Overweight or obesity
\n
\n Target population for LX9851 Phase 1 investigation
\n
\n <\/p>\n
\n $1.72
\n Last Close
\n <\/p>\n
\n Volume
\n Volume 6,237,288 is 2.27x the 20-day average of 2,753,285, indicating elevated trading interest ahead of this news.
\n
\n high
\n
\n <\/p>\n
\n Technical
\n Price at $1.56 is trading above the 200-day MA of $1.26, despite a -3.7% move over the prior day.
\n <\/p>\n
LXRX fell 3.7% pre-news with high volume. Peers showed mixed moves: FULC -3.84%, INBX -4.65%, SLDB -5.76%, while ATXS rose 0.8%. Momentum data show both up and down moves across names, pointing to stock-specific dynamics rather than a clean sector-wide trend.<\/p>\n
Pattern Detected<\/p>\n Clinical trial headlines have produced volatile moves for LXRX, including both strong rallies and sharp drawdowns, showing that data and regulatory nuances materially sway reactions.<\/p>\n Recent Company History<\/p>\n Over the past year, Lexicon\u2019s story has centered on clinical and regulatory progress across multiple programs. Clinical-trial news included positive HFpEF data for sotagliflozin and an End-of-Phase 2 FDA meeting clearing pilavapadin for Phase 3 design talks, alongside a sharply negative reaction to Phase 2b PROGRESS topline results. Today\u2019s LX9851 Phase 1 initiation builds on that pipeline narrative and follows the 10-K\u2019s description of LX9851\u2019s licensing to Novo Nordisk with substantial potential milestone and royalty economics.<\/p>\n -17.0%<\/p>\n Average Historical Move In the last 12 months, Lexicon issued 5 clinical-trial headlines averaging a -17.01% next-day move, with both strong gains and steep losses. The LX9851 Phase 1 start continues this pattern of market sensitivity to clinical updates.<\/p>\n Clinical news shows progression from Phase 2b pilavapadin data to an End-of-Phase 2 FDA meeting, plus expanding sotagliflozin datasets, now complemented by LX9851\u2019s transition into Phase 1 under Novo Nordisk.<\/p>\n
“Novo Nordisk has initiated a Phase 1 study with LX9851, a first-in-class…”<\/p>\n Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.<\/p>\n
<\/p>\n
“doses of LX9851 compared to placebo in 96 people with overweight or obesity.”<\/p>\n A placebo is an inactive pill, injection or procedure that looks and feels like the real treatment but contains no therapeutic ingredient, often called a sugar pill. Investors care because comparing a drug to a placebo reveals whether observed benefits come from the medicine itself or from expectation; clear superiority over placebo reduces regulatory and commercial risk, much like a blind taste test proves a new recipe really tastes better.<\/p>\n
<\/p>\n
“investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of…”<\/p>\n Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company\u2019s success and valuation in the healthcare industry.<\/p>\n
<\/p>\n
“safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple…”<\/p>\n Pharmacodynamics is how a drug actually affects the body \u2014 the strength, type and duration of its effects and the relationship between dose and response. Think of it like how turning a thermostat changes room temperature: it shows what the drug does and how much is needed to get the desired effect. Investors care because these properties drive clinical success, dosing convenience, safety profile and competitive advantage, all of which influence commercial potential and regulatory approval.<\/p>\n
<\/p>\n
“LX9851 is a first-in-class, oral non-incretin candidate being developed…”<\/p>\n Non-incretin describes a drug, treatment, or biological effect that works without involving incretins\u2014gut hormones (such as GLP\u20111) that help control insulin and blood sugar. For investors, labeling a therapy non-incretin signals a different mechanism of action, which can mean distinct safety, effectiveness, regulatory hurdles and market positioning; think of it as choosing a different engine type with its own costs, benefits and customer niche.<\/p>\n
<\/p>\n AI-generated analysis. Not financial advice.<\/p>\n
LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders<\/p>\n Lexicon has earned a second of three potential $10 million near-term milestone payments and is eligible to receive up to $1 billion in total upfront and milestone payments from the collaboration, plus royalties on net sales<\/p>\n THE WOODLANDS, Texas, March 23, 2026 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX<\/a>) and Novo Nordisk A\/S today announced that Novo Nordisk has initiated a Phase 1 study with LX9851, a first-in-class, oral non-incretin development candidate.<\/p>\n In March 2025, Lexicon signed an exclusive license agreement with Novo Nordisk for LX9851 in obesity and associated metabolic disorders. Under the terms of the agreement, Novo Nordisk obtained an exclusive, worldwide license to develop, manufacture and commercialize LX9851 in all indications.<\/p>\n Lexicon has earned a second $10 million milestone payment in 2026 from Novo Nordisk following initial dosing requirements in the Phase 1 study and is eligible for a third $10 million milestone payment that may be achieved later this year. In total, Lexicon is eligible to receive up to $1 billion in upfront and potential development, regulatory and sales milestone payments. Lexicon is also entitled to tiered royalties on net sales of LX9851.<\/p>\n \u201cWe are thrilled with the progress of the Novo Nordisk team on initiating the clinical development of LX9851,\u201d said Mike Exton, CEO and director of Lexicon. \u201cThe talented team at Novo Nordisk has recognized the significant potential for LX9851, a novel, oral candidate for obesity and has moved swiftly to advance the program in its pipeline. We believe LX9851 has the potential to become a differentiated approach in the next phase of treatments for obesity and metabolic disease.\u201d<\/p>\n \u201cWe are excited about the potential of LX9851 and pleased to take it into clinical testing to further explore the potential of the candidate,\u201d said Jacob Sten Petersen, Senior Vice President and Head of Global Research at Novo Nordisk. \u201cLX9851 offers a novel approach to the treatment of obesity and related metabolic conditions. It is an important addition to our pipeline of potential treatment options as we look to meet the diverse needs of people living with obesity, diabetes and their associated comorbidities.\u201d<\/p>\n The Phase 1 study is investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of LX9851 compared to placebo in 96 people with overweight or obesity. The trial is expected to be completed in the first quarter of 2027.<\/p>\n About LX9851 About Lexicon Pharmaceuticals\u00a0 About Novo Nordisk Safe Harbor Statement\u00a0\u00a0\u00a0
\n
\n
\n Date
\n Event
\n Sentiment
\n Move
\n Catalyst
\n
\n
\n
\n
\n
\n Jan 21
\n
\n
\n End-of-Phase 2 FDA<\/a>
\n
\n
\n
\n Positive
\n
\n
\n
\n +19.1%
\n
\n
\n
\n FDA raised no objections to advancing pilavapadin into Phase 3.
\n
\n
\n
\n
\n Dec 05
\n
\n
\n HFpEF adipose data<\/a>
\n
\n
\n
\n Neutral
\n
\n
\n
\n -1.4%
\n
\n
\n
\n Presentation of sotagliflozin adipose distribution data at CVCT 2025.
\n
\n
\n
\n
\n Nov 08
\n
\n
\n HFpEF efficacy data<\/a>
\n
\n
\n
\n Positive
\n
\n
\n
\n +13.6%
\n
\n
\n
\n Statistically significant HFpEF benefits without diabetes in SOTA P CARDIA trial.
\n
\n
\n
\n
\n Mar 03
\n
\n
\n Phase 2b PROGRESS topline<\/a>
\n
\n
\n
\n Negative
\n
\n
\n
\n -58.2%
\n
\n
\n
\n PROGRESS met objectives but missed primary endpoint statistical significance.
\n
\n
\n
\n
\n Mar 02
\n
\n
\n PROGRESS results preview<\/a>
\n
\n
\n
\n Neutral
\n
\n
\n
\n -58.2%
\n
\n
\n
\n
\n
\n Announcement of upcoming Phase 2b PROGRESS topline results webcast.
\n
\n
\n
\n
<\/p>\n
\n clinical trial<\/p>\n
\n The stock moved +5.1% in the session following this news. A strong positive reaction aligns with the significance of a first-in-class obesity candidate entering Phase 1 under a major partner. Past clinical headlines produced large moves, including both rallies and steep declines, so volatility around LX9851 updates would not be unusual. Investors could weigh the $10 million milestones and eligibility for up to $1 billion in payments against trial execution risk and broader biotech sentiment.
\n <\/p>\n
\n
\n phase 1
\n
\n medical
\n
\n
<\/p>\n
\n
\n placebo
\n
\n medical
\n
\n
<\/p>\n
\n
\n pharmacokinetics
\n
\n medical
\n
\n
<\/p>\n
\n
\n pharmacodynamics
\n
\n medical
\n
\n
<\/p>\n
\n
\n non-incretin
\n
\n medical
\n
\n
<\/p>\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n 03\/23\/2026 – 07:30 AM
\n
\n
<\/p>\n
LX9851, discovered by Lexicon and in development by Novo Nordisk, is a potent and selective oral small molecule inhibitor of Acyl CoA Synthetase 5 (ACSL5)\u200b. ACSL5 plays a key role in the metabolic pathway which regulates fat accumulation and energy balance. Additionally, LX9851 may activate the ileal brake mechanism leading to increased satiety by delaying gastric emptying and suppressing appetite. Preclinical\u00a0in vivo\u00a0efficacy data presented at Obesity Week 2024<\/a> show that LX9851, when combined with semaglutide, significantly reduced weight, food intake and fat mass compared to semaglutide alone. Separately, LX9851 mitigated weight regain and had positive effects on liver steatosis when introduced after semaglutide discontinuation.<\/p>\n
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients\u2019 lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity and metabolic disorders, and other cardiometabolic indications. For additional information, please visit www.lexpharma.com<\/a>.<\/p>\n
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease.<\/p>\n
This press release contains \u201cforward-looking statements,\u201d including statements relating to the preclinical and clinical development of LX9851, Lexicon\u2019s financial position and long-term outlook on its business, growth and future operating results, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management\u2019s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon\u2019s ability to meet its capital requirements, conduct preclinical and clinical development and obtain necessary regulatory approvals of its other drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon\u2019s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under \u201cRisk Factors\u201d in Lexicon\u2019s annual report on Form 10-K for the year ended\u00a0December 31, 2025\u00a0and other subsequent disclosure documents filed with the\u00a0Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.\u00a0\u00a0<\/p>\n
![\"\"](\"https:\/\/ml.globenewswire.com\/media\/MzFmNTk4ZjItYzc5Zi00OTM5LWJlNGQtMzBkMzAwNjE4OWM5LTEwMTU1NDAtMjAyNi0wMy0yMy1lbg==\/tiny\/Lexicon-Pharmaceuticals-Inc-.png\")